Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perspectives for TNF-alpha-targeting therapies.

Hanns-Martin Lorenz1, Joachim R Kalden

  • 1Institute for Clinical Immunology and Rheumatology, Department of Medicine, University of Erlangen-Nuremberg, Germany. Hannes.Lorenz@med3.imed.uni-erlangen.de

Arthritis Research
|July 12, 2002
PubMed
Summary

Rheumatoid arthritis (RA) treatment shows promise with novel biologic agents targeting TNF-alpha. Combination therapy, like infliximab and methotrexate, significantly reduced joint destruction in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Annals of the rheumatic diseases·2026
Same author

Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.

Science translational medicine·2026
Same author

Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.

Nature medicine·2026
Same author

A deep learning-based computational pipeline predicts developmental outcome in retinal organoids.

PLoS biology·2026
Same author

Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis.

Journal of innate immunity·2025
Same author

Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.

Rheumatology (Oxford, England)·2025

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a prevalent autoimmune disease causing joint destruction.
  • Current disease-modifying antirheumatic drugs (DMARDs) like methotrexate manage symptoms but don't halt joint damage.
  • Understanding RA pathogenesis has identified inflammatory mediators as therapeutic targets.

Purpose of the Study:

  • To review novel therapeutic agents for RA, focusing on TNF-alpha-targeted therapies.
  • To evaluate the efficacy of biologic agents, including monoclonal antibodies and receptor constructs.
  • To discuss combination therapies and future directions in RA treatment.

Main Methods:

  • Review of clinical trials and studies on novel RA therapies.
  • Analysis of data from trials investigating anti-TNF-alpha agents.

Related Experiment Videos

  • Evaluation of combination therapy efficacy, including infliximab and methotrexate.

    • Main Results:

    • Anti-TNF-alpha agents, alone or combined with methotrexate, demonstrate efficacy in RA treatment.
    • Combination therapy with infliximab and methotrexate showed no median radiological progression over 12 months.
    • Other TNF-alpha-directed agents like etanercept show encouraging results.

    Conclusions:

    • Novel biologic agents targeting TNF-alpha represent a significant advancement in RA therapy.
    • Combination therapies hold promise for halting or slowing joint destruction in RA.
    • Further research into TNF-alpha-targeted therapies and combination partners is warranted.